A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008 Meeting Abstract
| Authors: | Braunstein, L. Z.; Mitchell, M.; Bandos, H.; Sikov, W. M.; Khan, A. J.; Chen, P. Y.; Ganz, P. A.; Jagsi, R.; White, J. R.; Cecchini, R. S.; Kang, H.; Puhalla, S. L.; Bolton, K. L.; Connolly, E.; Stringer-Reasor, E. M.; Gergelis, K.; Julian, T. B.; Mamounas, E. P.; Wolmark, N. |
| Abstract Title: | A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008 |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406302 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS613 |
| Notes: | Meeting Abstract: TPS613 -- Source: Wos |
